OCULAR THERAPEUTIX INC's ticker is OCUL and the CUSIP is 67576A100. A total of 116 filers reported holding OCULAR THERAPEUTIX INC in Q4 2022. The put-call ratio across all filers is 0.82 and the average weighting 0.9%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $142,053 | -24.8% | 20,768 | 0.0% | 0.01% | -25.0% |
Q1 2024 | $188,989 | +104.0% | 20,768 | 0.0% | 0.01% | +100.0% |
Q4 2023 | $92,625 | +42.0% | 20,768 | 0.0% | 0.00% | +33.3% |
Q3 2023 | $65,212 | -72.4% | 20,768 | -54.6% | 0.00% | -70.0% |
Q2 2023 | $235,900 | -2.1% | 45,717 | 0.0% | 0.01% | -16.7% |
Q1 2023 | $240,929 | -91.1% | 45,717 | -95.3% | 0.01% | -90.8% |
Q4 2022 | $2,712,327 | -56.6% | 965,241 | -35.9% | 0.13% | -59.4% |
Q3 2022 | $6,252,000 | +6.1% | 1,506,456 | +2.8% | 0.32% | +6.6% |
Q2 2022 | $5,892,000 | -7.9% | 1,465,702 | +13.5% | 0.30% | +24.2% |
Q1 2022 | $6,395,000 | -13.3% | 1,291,905 | +22.1% | 0.24% | -10.3% |
Q4 2021 | $7,372,000 | -13.2% | 1,057,727 | +24.5% | 0.27% | -11.7% |
Q3 2021 | $8,496,000 | -51.0% | 849,600 | -30.6% | 0.31% | -51.3% |
Q2 2021 | $17,349,000 | -18.3% | 1,223,500 | -5.5% | 0.63% | -17.6% |
Q1 2021 | $21,248,000 | -13.8% | 1,294,850 | +8.7% | 0.77% | -6.2% |
Q4 2020 | $24,648,000 | – | 1,190,703 | – | 0.82% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SUMMER ROAD LLC | 5,618,861 | $79,675,000 | 100.00% |
Opaleye Management Inc. | 6,480,000 | $91,886,000 | 15.26% |
DELTEC ASSET MANAGEMENT LLC | 2,167,313 | $30,732,000 | 4.23% |
Kamunting Street Capital Management, L.P. | 624,201 | $8,851,000 | 3.58% |
GREAT POINT PARTNERS LLC | 919,887 | $13,044,000 | 2.74% |
Endurant Capital Management LP | 570,970 | $8,096,000 | 2.22% |
Rubric Capital Management LP | 2,156,542 | $30,580,000 | 1.92% |
Affinity Asset Advisors, LLC | 250,000 | $3,545,000 | 1.27% |
Altium Capital Management LP | 256,152 | $3,632,000 | 0.84% |
Ikarian Capital, LLC | 700,000 | $9,928,000 | 0.80% |